• Profile
Close

Fixed-ratio combination of insulin degludec and liraglutide (IDegLira) improves cardiovascular risk markers in patients with type 2 diabetes uncontrolled on basal insulin

Diabetes, Obesity and Metabolism Mar 20, 2019

Vilsboll T, et al. - In this study, investigators quantified data to determine the consequences of insulin degludec/liraglutide fixed-ratio combination (IDegLira) vs comparators on cardiovascular (CV) risk markers from DUAL II vs insulin degludec, DUAL V vs insulin glargine 100 units/mL, and DUAL VII vs basal-bolus therapy in subjects adjusted for sex, age (< 65 years vs ≥ 65 years), and duration of diabetes (< 10 years or ≥ 10 years). In all, treatment outcomes favored IDegLira in many cases for variations from baseline in HbA1c, body weight, systolic blood pressure, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol. They investigators observed higher heart rates and diastolic blood pressure levels with IDegLira vs comparators in males. Findings supported an association of IDegLira with a general improvement in CV risk markers vs basal insulin or basal-bolus therapy after 26 weeks of treatment.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay